the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell((R)), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell((R)) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins.
For more information on Bioheart, visit www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) Page: 1 2 3 Related biology technology :1
. Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors2
. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 20083
. Bioheart, Inc. Announces Financial Results for First Quarter 20084
. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements5
. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 20086
. Bioheart, Inc. to Transfer to Nasdaq Capital Market7
. Bioheart, Inc., Added to Russell Microcap Index8
. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer9
. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients10
. Bioheart, Inc., Announces Management Change11
. Bioheart, Inc. Announces Results of Annual Meeting